Autopsy report · NCT03657420

Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma

“Funding withdrawn by sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Massachusetts General Hospital

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma

Interventions

ABI-009; Pomalidomide; Dexamethasone

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads
  “Sponsor withdrew funding” (96% match in meaning)
• ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children
  “Withdrawal of funding from primary sponsor” (89% match in meaning)
• Lucentis for New Onset Neovascular Glaucoma
  “Company withdrew funding/sponsorship” (89% match in meaning)
• Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
  “funding withdrawn” (87% match in meaning)
• An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
  “Sponsor withdrawn” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.